Acura Pharmaceuticals Inc. (NASDAQ:ACUR)

CAPS Rating: 3 out of 5

A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.


Player Avatar zzlangerhans (99.85) Submitted: 11/7/2013 7:31:18 PM : Outperform Start Price: $1.67 ACUR Score: -83.06

My first Acura green thumb didn't work out so well due to a combination of poor timing on my part with poor tracking of the ticker by CAPS. Nevertheless, I'll make another bet that this company isn't quite ready to give up the ghost. The story of the stock has been a gradual decline which will eventually arrive at zero, with intermittent short-lived spikes due to disproportionate buying by naive retail investors on purported positive news. Another PR of pathetic revenues for doomed products Oxecta and Nexafed hasn't done wonders for the share price. It's easy to get burned playing stocks like this but the fun of riding the spike more than makes up for the pain of the decline.

Featured Broker Partners